NCT03563937 - Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon | Biotech Hunter

Enrollment

64,920

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

December 10, 2019

Study Completion Date

December 10, 2019

Conditions

Atrial Fibrillation

Interventions

DRUG

Phenprocoumon

Follow the physician's prescription.

DRUG

Apixaban

2.5 mg or 5 mg, twice daily

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

15 mg or 20 mg, once daily

DRUG

Edoxaban

30 mg or 60 mg, once daily

Trial Locations (1)

Many Locations, Multiple Locations